ESR1 and invasive breast carcinoma: Adjuvant hormonal therapy is advocated for all the women with positive ER/PgR status regardless of their age, menopausal status, grade, stage, and axillary lymph nodes status or tumor size [7-8,10]. Positivity for ER and PgR receptors in invasive breast carcinoma is found to be 70%-80% and 60%-70%, respectively [7-8]. In Asian countries, the prevalence of hormone receptor-positive tumors is lower than that in the western world [2-3]. However, the number of studies performed on the Asian population is also much less as compared to the west.